Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study

  • Isabelle Lacroix
  • Alain Berrebi
  • Daniel Garipuy
  • Laurent Schmitt
  • Yamina Hammou
  • Catherine Chaumerliac
  • Maryse Lapeyre-Mestre
  • Jean-Louis Montastruc
  • Christine Damase-Michel
Pharmacoepidemiology and Prescription


Patients and methods

In order to investigate the effects of exposure to buprenorphine compared with methadone during pregnancy, a prospective multicenter study was conducted in collaboration with maternity hospitals, maintenance therapy centers, and general practitioners involved in addiction care. Ninety pregnant women exposed to buprenorphine and 45 to metadone were selected for the study.


During pregnancy, some women were exposed to illicit agents: cannabis (42% in the buprenorphine group vs. 58% in the methadone-treated group), heroin (17% vs. 44%), or cocaine (3% vs. 11%). Pregnancies ended in 85 vs. 40 live births, one vs. two stillbirths, two vs. one spontaneous abortion, two vs. one voluntary termination, and one vs. one medical termination in the buprenorphine and the methadone groups, respectively. Newborns had a birth weight of 2,892 ± 506 g (buprenorphine) vs. 2,731 ± 634 g (methadone) and a body length of 47.6 ± 2.5 cm vs. 47.1 ± 3 cm. 18.8% vs. 10% of newborns were delivered before 37 weeks of amenorrhea. Neonatal withdrawal syndrome occurred more frequently in the methadone group (62.5% vs. 41.2, p = 0.03). After adjustment for heroin exposure in late pregnancy, rates of neonatal withdrawal were no longer different between the methadone and buprenorphine groups. Twenty-one babies (84%) in the methadone group and 20 (57%) in the buprenorphine group (p = 0.03) required opiate treatment.


We did not observe more frequent malformations or cases of withdrawal syndrome in the buprenorphine group than in the methadone-treated group. Buprenorphine appears to be as safe as the currently approved substitute methadone considered to date as the reference treatment for pregnant opioid-dependent women.


Pregnancy Buprenorphine Methadone Neonate Neonatal withdrawal Pharmacoepidemiology 



The authors thank Mariana Titorov for her editorial assistance, Dr. Catherine Alexandre, Evelyne Armand, Dr. Jacques Barsony, Dr. Bernard Beauséjour, Dr. Charles Bensehmoun, Dr. Jérôme Boucard, Dr. Philippe Cadilhac, Dr. Hélène Charitat, Dr. Marie Crecqui, Dr. Philippe De Lapanouse, Dr. Elisabeth Elefant, Dr. Valérie Fuzier, Dr. André Glibert, Dr. Jérôme Heysch de la Borde, Dr. Marie-Annick Lebreton, Dr. Nadir Messaadi, Dr. Georges Noujaïm, Dr. Olivier Parant, Dr. Jean-Yves Redon, Dr. Francis Saint-Dizier, Martine Segueilla, and Catherine Wahart for their participation (inclusion of pregnant women). With the support of the French Programme Hospitalier de Recherche Clinique.

Declarations of interest



  1. 1.
    Farid WO, Dunlop SA, Tait RJ, Hulse GK (2008) The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data. Curr Neuropharmacol 6:125–150PubMedCrossRefGoogle Scholar
  2. 2.
    Hulse GK, Milne E, English DR (1997) The relationship between maternal use of heroin and methadone and infant birth weight. Addiction 92:1571–1579PubMedCrossRefGoogle Scholar
  3. 3.
    Marquet P, Chevrel J, Lavignasse P, Merle L, Lachatre G (1997) Buprenorphine withdrawal syndrome in a new-born. Clin Pharmacol Ther 62:569–571PubMedCrossRefGoogle Scholar
  4. 4.
    Regini P, Cutrone M, Donzelli F, Flora PG, Monsanto G (1998) Neonatal buprenorphine withdrawal syndrome, what is the right therapy? Pediatr Med Chir 20:67–69PubMedGoogle Scholar
  5. 5.
    Fischer G, Etzersdorfer P, Eder H, Jagsch R, Langer M, Weninger M (1998) Buprenorphine maintenance in pregnant opiate addicts. Eur Addict Res 4:32–36PubMedCrossRefGoogle Scholar
  6. 6.
    Hervé F, Quenum S (1998) Buprenorphine (Subutex) and neonatal withdrawal syndrome. Arch Pédiatr 5:206–207PubMedCrossRefGoogle Scholar
  7. 7.
    Eder H, Rupp I, Peternell A, Fischer G (2001) Buprenorphine in pregnancy. Psychiatr Prax 228:267–269CrossRefGoogle Scholar
  8. 8.
    Lejeune C, Aubisson S, Simmat-Durand L, Cneude F, Piquet M, Gourarier L et al (2001) Withdrawal syndromes of new-borns of pregnant drug abusers maintained under methadone or high dose buprenorphine: 246 cases. Ann Méd Interne 152:21–27Google Scholar
  9. 9.
    Rohrmeister K, Bernert G, Langer M, Fischer G, Weninger M, Pollak A (2001) Opiate addiction in gravidity—consequences for the new-born. Results of an interdisciplinary treatment concept. Z Geburtshilfe Neonatol 205:224–230PubMedCrossRefGoogle Scholar
  10. 10.
    Reisinger M (1997) Use of buprenorphine during pregnancy. Res Clin Forums 2:43–45Google Scholar
  11. 11.
    Jernite M, Viville B, Escande B, Brettes JP, Messer J (1999) Buprenorphine and pregnancy. Analysis of 24 cases. Arch Pédiatr 6:1179–1185PubMedCrossRefGoogle Scholar
  12. 12.
    Auriacombe M, Afflelou S, Lavignasse P, Lafitte C, Roux D, Daulouede JP et al (1999) Pregnancy, abortion and delivery in a cohort of heroin dependent patients treated with drug substitution (methadone and buprenorphine) in Aquitaine. Presse Méd 28:177PubMedGoogle Scholar
  13. 13.
    Fischer G, Johnson RE, Eder H, Jagsch R, Peternell A, Weninger M et al (2000) Treatment of opioid-dependent pregnant women with buprenorphine. Addiction 95:239–244PubMedCrossRefGoogle Scholar
  14. 14.
    Johnson RE, Jones HE, Jasinski DR, Svikis DS, Haug NA, Jansson LM et al (2001) Buprenorphine treatment of pregnant opioiddependent women: maternal and neonatal outcomes. Drug Alcohol Depend 63:97–103PubMedCrossRefGoogle Scholar
  15. 15.
    Finnegan LP, Connaughton JF, Kron RE (1975) Neonatal abstinence syndrome assessment and management. Addict Disord Their Treat 1:141–158Google Scholar
  16. 16.
    Jones HE, Johnson RE, Jasinski DR, O’Grady KE, Chisholm CA, Choo RE et al (2005) Buprenorphine vs methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 79:1–10PubMedCrossRefGoogle Scholar
  17. 17.
    Binder T, Vavrinková B (2008) Prospective randomised comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the outpatient department. Neuro Endocrinol Lett 29:80–86PubMedGoogle Scholar
  18. 18.
    Fischer G, Ortner R, Rohrmeister K, Jagsch R, Baewert A, Langer M et al (2006) Methadone vs buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 101:275–281PubMedCrossRefGoogle Scholar
  19. 19.
    Martinek IE, Vial Y, Hohlfeld P (2006) Prise en charge de la mort in utero: quel bilan proposer ? La Revue Sage-femme 5:299–311CrossRefGoogle Scholar
  20. 20.
    Thaithumyanon P, Limpongsanurak S, Praisuwanna P, Punnahitanon S (2005) Perinatal effects of amphetamine and heroin use during pregnancy on the mother and infant. J Med Assoc Thai 88:1506–1513PubMedGoogle Scholar
  21. 21.
    Kennare R, Heard A, Chan A (2005) Substance use during pregnancy: risk factors and obstetric and perinatal outcomes in South Australia. Aust N Z J Obstet Gynaecol 45:220–225PubMedCrossRefGoogle Scholar
  22. 22.
    Kakko J, Heilig M, Sarman I (2008) Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend 96:69–78PubMedCrossRefGoogle Scholar
  23. 23.
    Brown HL, Britton KA, Mahaffey D (1998) Methadone maintenance in pregnancy: a reappraisal. Am J Obstet Gynecol 179:459–463PubMedCrossRefGoogle Scholar
  24. 24.
    Aubisson S, Cneude F, Lejeune C, Simmat-Durand L (2001) Etude comparative des nouveau-nés de mères substituées par méthadone ou buprénorphine haut dosage (HD) pendant la grossesse. La lettre du pharmacologue 15:45–48Google Scholar
  25. 25.
    Fraser AC (1976) Drug addiction in pregnancy. Lancet 2:896–899PubMedCrossRefGoogle Scholar
  26. 26.
    (2005) Grossesse chez les patientes dépendantes aux opiacés. Prescrire 267:836–841Google Scholar
  27. 27.
    De Vigan C, Khoshnood B, Lhomme A, Vodovar V, Goujard J, Goffinet F (2005) Prévalence et diagnostic prénatal des malformations en population parisienne: vingt ans de surveillance par le Registre des malformations congénitales de Paris. J Gynécol Obstét Biol Reprod 34(1):8–16Google Scholar
  28. 28.
    Lacroix I, Hurault C, Sarramon MF, Guitard C, Berrebi A, Grau M et al (2009) Prescription of drugs during pregnancy: a study using EFEMERIS*, the new French database. Eur J Clin Pharmacol 65:839–846PubMedCrossRefGoogle Scholar
  29. 29.
    Kayemba-Kay’s S, Laclyde JP (2003) Buprenorphine withdrawal syndrome in newborns: a report of 13 cases. Addiction 98:1599–1604PubMedCrossRefGoogle Scholar
  30. 30.
    Kahila H, Saisto T, Kivitie-Kallio S, Haukkamaa M, Halmesmäki E (2007) A prospective study on buprenorphine use during pregnancy: effects on maternal and neonatal outcome. Acta Obstet Gynecol Scand 86:185–190PubMedCrossRefGoogle Scholar
  31. 31.
    Committee on Drugs (1983) Neonatal drug withdrawal. Pediatrics 72:895–902Google Scholar
  32. 32.
    Dawe S, Gerada C, Strang J (1992) Establishment of a liaison service for pregnant opiate-dependent women. Br J Addict 87:867–871PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Isabelle Lacroix
    • 1
  • Alain Berrebi
    • 2
  • Daniel Garipuy
    • 3
  • Laurent Schmitt
    • 4
  • Yamina Hammou
    • 5
  • Catherine Chaumerliac
    • 6
  • Maryse Lapeyre-Mestre
    • 1
  • Jean-Louis Montastruc
    • 7
  • Christine Damase-Michel
    • 7
  1. 1.Centre Hospitalier Universitaire de Toulouse, Laboratoire de Pharmacologie Médicale et Clinique, Centre d’Evaluation et d’Information sur la Pharmacodépendance et d’AddictovigilanceINSERM U1027, Université de ToulouseToulouseFrance
  2. 2.Service de Gynécologie ObstétriqueCentre Hospitalier Universitaire de ToulouseToulouseFrance
  3. 3.Hôpital Joseph Ducuing, Réseau ville-hôpital PassageToulouseFrance
  4. 4.Centre Hospitalier Universitaire de Toulouse, Centre de soins aux toxicomanesToulouseFrance
  5. 5.Service de Gynécologie ObstétriqueCentre Hospitalier Universitaire de LilleToulouseFrance
  6. 6.Laboratoire de Pharmacologie Médicale et CliniqueCentre Hospitalier Universitaire de ToulouseToulouseFrance
  7. 7.Centre Hospitalier Universitaire de Toulouse, Laboratoire de Pharmacologie Médicale et CliniqueINSERM U1027, Université de ToulouseToulouseFrance

Personalised recommendations